Aug 15 2012
"When you're dealing with a global public health crisis, having an international presence isn't just advisable -- it is imperative," Margaret McGlynn, president and CEO of the International AIDS Vaccine Initiative (IAVI), writes in this post in USAID's "Impact" blog, adding, "That's why the [IAVI], in partnership with USAID, has worked diligently over the past several years to establish itself as a truly global non-profit partner." She continues, "IAVI has created an enviable network of research centers in sub-Saharan Africa dedicated to assessing novel AIDS vaccine candidates in clinical trials and conducting supporting epidemiological studies on HIV," and writes that these "partnerships have made meaningful contributions to the research capacity of many developing countries -- a capability that is now helping local researchers tackle other diseases" (8/13).
 This article was reprinted from kaiserhealthnews.org with permission from the Henry J. Kaiser Family Foundation. Kaiser Health News, an editorially independent news service, is a program of the Kaiser Family Foundation, a nonpartisan health care policy research organization unaffiliated with Kaiser Permanente.
|
Spermidine regulates RIPK1 to combat diabetes and vascular damage